<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400748</url>
  </required_header>
  <id_info>
    <org_study_id>15</org_study_id>
    <nct_id>NCT03400748</nct_id>
  </id_info>
  <brief_title>ANET Electrosurgery Applicator Pilot Evaluation Study</brief_title>
  <official_title>ANET Electrosurgery Applicator Pilot Evaluation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spiration, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spiration, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the preliminary safety and performance of the Electrosurgery Applicator (ANET
      device) during and after bronchoscopic ablation of a target pulmonary nodule/tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single arm, single center study that will evaluate the
      effectiveness of the ANET Electrosurgery Applicator in up to 10 subjects.

      Subjects who consent to participate in this study will have a lung tumor that is scheduled to
      be removed surgically as part of their normal treatment. During the surgical procedure, just
      prior to resection the subject's tumor will be treated with the ANET device. The ANET device
      uses a bronchoscope to reach the tumor. Ultrasound on the bronchoscope, CT, and X-rays are
      used to make sure the ANET device is in the tumor. Once in the tumor, the ANET device uses
      radio-frequency (RF) ablation to treat the tumor. After standard surgical resection the tumor
      and surrounding tissue is evaluated to characterize the effect of the ANET.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 23, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ANET related peri-procedural Adverse Events</measure>
    <time_frame>Day 0</time_frame>
    <description>The incidence of reported adverse events and serious adverse events related to the ANET device or procedure</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>RF Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-arm study where subjects receive RF ablation prior to a scheduled surgical resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RF Ablation</intervention_name>
    <description>The intervention consists of a bronchoscopic approach to ablate lung tumors with radio-frequency energy.</description>
    <arm_group_label>RF Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject with Stage I or Stage II primary lung cancer or metastatic lung tumor

          2. Pathological proof of target nodule/tumor type and malignancy

          3. Target nodule/tumor which can be accessed via EBUS bronchoscopy

          4. Resection/surgical candidate

          5. Participants must be at least 18 years old and able to provide consent

        Exclusion criteria:

          1. Subjects in whom flexible bronchoscopy is contraindicated

          2. Target nodule &lt; 1.0 cm

          3. Prior radiation or neo adjuvant chemotherapy of the target nodule/tumor

          4. Any comorbidity that the investigator feels would interfere with the safety of the
             subject or the evaluation of study objectives

          5. Pacemaker, implantable cardioverter, or other electronic implantable device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electrosurgery</keyword>
  <keyword>RF ablation</keyword>
  <keyword>Minimally invasive</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>Lung metastasis</keyword>
  <keyword>Lung tumor</keyword>
  <keyword>Primary</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Endobronchial ultrasound</keyword>
  <keyword>EBUS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

